In the FINEARTS-HF trial (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure), the effects of the selective nonsteroidal mineralocorticoid receptor antagonist finerenone were compared with those of placebo in patients with HFmrEF/HFpEF. This evidence concerns the gene NR3C2 and hydrops fetalis.